VFA
VYGR icon

Valeo Financial Advisors’s Voyager Therapeutics VYGR Stock Holding History

Valeo Financial Advisors’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-20
Closed – – 2200
2020
Q4 		$0 Buy
+20
New +$192 ﹤0.01% 1867

Other funds holding VYGR

TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
WHCM
Wolf Hill Capital Management Greenwich, Connecticut $1.03B AUM 80.44% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Valeo Financial Advisors's VYGR Position: Q1 2021 in Review

Valeo Financial Advisors sold out of Voyager Therapeutics (VYGR) in Q1 2021, closing a stake of 20 shares.

Valeo Financial Advisors first reported a position in VYGR in Q4 2020 and held it in 1 quarter. The position peaked at $0 in Q4 2020. 101 funds tracked by Wall St. Rank hold VYGR as of Q1 2021.

  • Valeo Financial Advisors reported no remaining Voyager Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Valeo Financial Advisors sold 20 Voyager Therapeutics shares in Q1 2021.
  • Valeo Financial Advisors first reported a position in Voyager Therapeutics in Q4 2020 and held it in 1 quarter.
  • Valeo Financial Advisors's Voyager Therapeutics position peaked at $0 in Q4 2020.
  • 101 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q1 2021.

Based on Valeo Financial Advisors's 13F filing for Q1 2021, filed 12 Apr 2021.